Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer (NCT05575440) | Clinical Trial Compass
RecruitingNot Applicable
Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer
United States24 participantsStarted 2022-04-22
Plain-language summary
This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subject has biopsy-proven papillary or follicular thyroid cancer
* Subject is clinically indicated for 123I-SPECT/CT total body iodine (TBI) scan
* Subject agrees to undergo 18F-TFB PET/CT scan following TBI scan
* Karnofsky performance status of \>= 50 (or Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] equivalent)
* Subject is able to be scanned - able to lie still on SPECT/CT and PET/CT scanner table for up to 65 minutes (min)
* Age 18 or older
* Ability to understand a written informed consent document, and the willingness to sign it
* Subject is not pregnant
Exclusion Criteria:
* Contrast-enhanced CT within 4 last weeks
* Amiodarone within last 4 months
* Ingested iodine, kelp tablets, Lugols iodine, or potassium iodide (SSKI) within 2 weeks
* Unable to lie flat, still or tolerate a PET scan
* Applied betadine, iodoform, or quick tanning products to skin within last two weeks
* If using medication withdrawal for stimulation, then exclude if thyroid stimulating hormone (TSH) level \< 25
* Taken anti-thyroid medication within 1 week
* Subject is breastfeeding
* Positive pregnancy test
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Descriptive summaries of detected lesions
Timeframe: Up to 2 years
2
Conspicuities and diagnostic confidence scores for a given lesion